Xeris Biopharma Holdings (XERS) Amortizatization of Intangibles (2020 - 2026)

Xeris Biopharma Holdings has reported Amortizatization of Intangibles for 7 years, with the latest figure at $163000.0 in Q1 2026.

• For the quarter ending Q1 2026, Amortizatization of Intangibles rose 38.14% year-over-year to $163000.0; the trailing twelve-month figure through Mar 2026 stood at $6.1 million (up 431.64% YoY), and the FY2025 full-year result was $537000.0, down 28.11% from the prior year.
• Amortizatization of Intangibles for Q1 2026 stood at $163000.0, down from $537000.0 in the prior quarter.
• The five-year high for Amortizatization of Intangibles was $2.7 million in Q1 2022, with the low at -$7.4 million in Q4 2024.
• Historically, Amortizatization of Intangibles has averaged $787411.8 across 5 years, with a median of $2.7 million in 2022.
• Annual changes were most pronounced in 2022 — Amortizatization of Intangibles surged 1860.39% — and 2023, when it slumped 20183.33%.
• Xeris Biopharma Holdings' Amortizatization of Intangibles stood at -$36000.0 in 2022, then tumbled by 20183.33% to -$7.3 million in 2023, then declined by 1.14% to -$7.4 million in 2024, then surged by 107.27% to $537000.0 in 2025, then tumbled by 69.65% to $163000.0 in 2026.
• The last three Amortizatization of Intangibles figures came in at $163000.0 (Q1 2026), $537000.0 (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.